The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review

References

• http://guidance.nice.org.uk/TA121/CostingTemplate/xls/English. 2007 Accessed 20 March 2010.
   Google Scholar
• Anderson E, Grant R, Lewis SC, Whittle IR. Randomized Phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br J Neurosurg 200822(3):339–49.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 20035(2):79–88.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005352(10):987–96.
   PubMed Web of Science ®Google Scholar
• (www.nice.org.uk/TA121). 2007
   Google Scholar
• Pan E, Mitchell S, Tsai J. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neuro-Oncol 200888(3):353–7.
   Google Scholar
• La Rocca R, Vitaz TW, Villanueva W, et al. A phase 2 study of multimodal therapy with surgery, carmustine (BCNU) wafer, radiation therapy (RT), and temozolomide (TMZ) in patients with newly diagnosed supratentorial malignant glioma (MG)Barcelona: EANO; 2008.
   Google Scholar
• Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable Carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol 201017(7):1740–6.
   PubMed Web of Science ®Google Scholar
• Affronti ML, Heery CR, II JEH, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009115(15):3501–11.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009110(3):583–8.
   PubMed Web of Science ®Google Scholar
• Ryken T, Carlisle T, Buatti J, et al. Treatment of adults with newly diagnosed glioblastoma multiforme or anaplastic astrocytoma with surgery, gliadel wafers and limited field radiation plus concomitant temozolomide followed by adjuvant temozolomide. J Clin Oncol 200826: abstr. 13003.
   Google Scholar
• Asher AL. Prospective analysis of temozolomide as adjuvant to Gliadel and radiation in newly diagnosed malignant glioma [abstract]. American Association of Neurological Surgeons. Washington, DC: American Association of Neurological Surgeons, 75th Annual Meeting 2007: A42860.
   Google Scholar
• Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 201033(4):441–9.
   PubMed Web of Science ®Google Scholar
• Noel G, Kehrly P, Schott R, et al. Adding biodegradable carmustine wafers before a stupp schedule does not alter outcome of patients with high grade brain tumor. Int J Radiat Oncol Biol Phys 200975(3):S247.
   Google Scholar
• Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006148(3):269–75; discussion 275.
   PubMed Web of Science ®Google Scholar
• http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. 2009 (version 3)
   Google Scholar
• Perry CAJ, Spithoff K, Laperriere N. Neuro-oncology Disease Site Group. Gliadel wafers in the treatment of malignant glioma: a clinical practice guidelineToronto (ON): Cancer Care Ontario (CCO) (Evidence-based series; no. 9–7), 2006.
   Google Scholar
• <http://sircamt.canceraquitaine.org/rca/documents/referentiels/RefGliomes.pdf>.
   Google Scholar
• Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 199741(1):44–8; discussion 48–9.
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 200815(10):2887–93.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 200910(5):459–66.
   PubMed Web of Science ®Google Scholar
• Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 20013(4):246–50.
   PubMed Web of Science ®Google Scholar
• Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin 200824(11):3239–57.
   PubMed Web of Science ®Google Scholar
• Barrie M, Couprie C, Dufour H, et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol 200516(7):1177–84.
   PubMed Web of Science ®Google Scholar
• Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 200927(8):1257–61.
   PubMed Web of Science ®Google Scholar
• Susan MC, Wendy S, Walter C, et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys 200459(4):1122–6.
   Google Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from Temozolomide in glioblastoma. N Engl J Med 2005352(10):997–1003.
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Carter J, et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 200915(3):1064–8.
   PubMed Web of Science ®Google Scholar
• http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid = 7346248. 2010.
   Google Scholar
• Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 200927(8):1275–9.
   PubMed Web of Science ®Google Scholar
• Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 200241(6):403–19.
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Esrailian E, Laine L, Chamberlain MC. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 200721(9):775–87.
   Google Scholar
• Sher D, Henson J, Avutu B, et al. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neuro-Oncol 200888(1):43–50.
   Google Scholar
• La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 200925(1):149–60.
   PubMed Web of Science ®Google Scholar
• Giese A, Bock HC, Kantelhardt SR, Rohde V. Risk management in the treatment of malignant gliomas with BCNU wafer implants. Cen Eur Neurosurg2010199–206.
   Google Scholar
• www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf. January 2009.
   Google Scholar